Andrew Martin
Child & Adolescent Psychiatry · San Antonio, TXNPI 1356434146
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 275 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 16.7% — the pattern of someone who eats at a lot of different presentations. Among child & adolescent psychiatry clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 275 payments — averaging $20.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Supernus Pharmaceuticals, Inc.$926
- Otsuka America Pharmaceutical, Inc.$861
- Takeda Pharmaceuticals U.S.A., Inc.$778
- Lundbeck LLC$572
- Johnson & Johnson$482
- Corium, LLC$408
- plus $2K from 16 others
What the payments were for
- Food & beverage$5,526100%
- Education$170%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 34 | $926 |
| Otsuka America Pharmaceutical, Inc. | 39 | $861 |
| Takeda Pharmaceuticals U.S.A., Inc. | 50 | $778 |
| Lundbeck LLC | 39 | $572 |
| Johnson & Johnson | 17 | $482 |
| Corium, LLC | 24 | $408 |
| Sunovion Pharmaceuticals Inc. | 14 | $255 |
| Neuronetics, Inc. | 3 | $254 |
| Collegium Pharmaceutical, Inc. | 12 | $168 |
| Teva Pharmaceuticals USA, Inc. | 7 | $160 |
| Ironshore Pharmaceuticals Inc. | 7 | $151 |
| Avanir Pharmaceuticals, Inc. | 5 | $100 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $95 |
| Neos Therapeutics, LP | 4 | $79 |
| Shire North American Group Inc | 4 | $73 |
| Adlon Therapeutics L.p. | 2 | $34 |
| Tris Pharma Inc | 2 | $33 |
| Sage Therapeutics, LLC | 2 | $29 |
| Arbor Pharmaceuticals, Inc. | 2 | $29 |
| Vertical Pharmaceuticals, LLC | 2 | $26 |
| Revance Therapeutics, Inc. | 1 | $15 |
| Alfasigma USA, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QELBREE$408
- REXULTI$241
- NEUROSTAR TMS THERAPY SYSTEM$172
- SPRAVATO$108
How this compares
$5,543 in reported general payments places this provider in the 90th percentile of 301 child & adolescent psychiatry providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 14 | $118,449 |
| ClozarilClozapine | 11 | $24,242 |
| Lurasidone Hcl | 20 | $18,319 |
| FetzimaLevomilnacipran Hcl | 13 | $6,065 |
| Olanzapine | 15 | $470 |
| Doxepin Hcl | 11 | $300 |
| Gabapentin | 12 | $285 |
| Lithium Carbonate | 12 | $199 |
| Aripiprazole | 19 | $180 |
| Citalopram HbrCitalopram Hydrobromide | 22 | $139 |
| Duloxetine Hcl | 24 | $119 |
Paid to pharmacies, not to this prescriber.
Other child & adolescent psychiatry in San Antonio
- Steven PliszkaSan Antonio$59K
- Mary Garcia HolguinSan Antonio$24K
- Maria DominguezSan Antonio$7K
- Amber MansoorSan Antonio$6K
- Thomas DemoorSan Antonio$5K
- Vanessa VelaSan Antonio$3K
- Marguerite HoganSan Antonio$3K
- Grace Salinas GarciaSan Antonio$2K
- Hector SamaniegoSan Antonio$2K
- Alain KaticBellaire$106K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.